Loading...
Loading...
Cyclacel
Pharmaceuticals, Inc.
CYC,
today announced that the first patient has been dosed in an
investigator-initiated, translational, Phase 2 clinical study at The
University of Texas MD Anderson Cancer Center.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: FDA
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in